The United States of America Food and Drug Administration recognises the importance of UGT1A1 pharmacogenetics in predicting toxicity to irinotecan and describes the association between reduced enzymatic activity of the UGT1A1*28 allele and neutropenia after drug administration in their summary of product characteristics. The gene discussed is UGT1A1; the disease is neutropenia.